SEK 3.35
(-0.3%)
Year | Inventory | Inventory Growth |
---|---|---|
2024 | 4.99 Million SEK | 137.29% |
2023 | 2.1 Million SEK | 18.66% |
2022 | 1.77 Million SEK | 0.0% |
2021 | - SEK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q4 | 4.99 Million SEK | -21.29% |
2024 Q3 | 6.34 Million SEK | -1.73% |
2024 Q2 | 6.45 Million SEK | 19.57% |
2024 Q1 | 5.4 Million SEK | 156.58% |
2023 FY | 2.1 Million SEK | 18.66% |
2023 Q1 | - SEK | 0.0% |
2023 Q4 | 2.1 Million SEK | 39.77% |
2023 Q3 | 1.5 Million SEK | 14.09% |
2023 Q2 | 1.32 Million SEK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AcuCort AB | -1.09 Million SEK | 554.504% |
AlzeCure Pharma AB (publ) | -2508.00 SEK | 199262.679% |
BioGaia AB (publ) | 181.2 Million SEK | 97.243% |
Enzymatica AB (publ) | 11.49 Million SEK | 56.561% |
Enorama Pharma AB (publ) | 4.29 Million SEK | -16.379% |
Gabather AB (publ) | -1772.00 SEK | 281984.876% |
Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
Moberg Pharma AB (publ) | 7.11 Million SEK | 29.796% |
Nanexa AB (publ) | 1.91 Million SEK | -161.381% |
ODI Pharma AB | - SEK | -Infinity% |
Orexo AB (publ) | 42.4 Million SEK | 88.219% |
Probi AB (publ) | 116.7 Million SEK | 95.72% |
Swedencare AB (publ) | 398.1 Million SEK | 98.745% |
Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 99.871% |
Toleranzia AB | -1.34 Million SEK | 472.761% |
Vivesto AB | - SEK | -Infinity% |